Savara (SVRA) News Today $4.67 -0.09 (-1.89%) Closing price 04:00 PM EasternExtended Trading$4.72 +0.05 (+1.18%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Savara Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion ImpairmentOctober 21 at 1:10 PM | businesswire.comWill Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?October 13, 2026 | finance.yahoo.comSavara Inc. (SVRA) - What Are Analysts Thinking About This Stock?October 13, 2026 | americanbankingnews.comSavara Inc. (NASDAQ:SVRA) Stock Has Average Target Price of $10.25 According to AnalystsOctober 13, 2026 | marketbeat.comSavara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026October 12, 2026 | businesswire.comSavara (NASDAQ:SVRA) Shares Climb 7.2% - Still a Buy?October 7, 2026 | marketbeat.comJPMorgan Initiates Savara at Overweight With $12 Price TargetOctober 7, 2026 | marketscreener.comMSavara (NASDAQ:SVRA) Coverage Initiated by Analysts at JPMorgan Chase & Co.October 7, 2026 | marketbeat.comSavara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street ZenOctober 4, 2026 | marketbeat.comSavara (NASDAQ:SVRA) Stock Falls 5.4% - Here's WhyOctober 2, 2026 | marketbeat.comBank of America Corp DE Buys 520,356 Shares of Savara Inc. $SVRASeptember 30, 2026 | marketbeat.comSavara (NASDAQ:SVRA) Raised to Hold at Wall Street ZenSeptember 26, 2026 | marketbeat.comSavara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?September 24, 2026 | rttnews.comSavara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...August 24, 2026 | uk.finance.yahoo.comSavara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026August 24, 2026 | businesswire.comSavara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo FinanceAugust 20, 2026 | finance.yahoo.comSavara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed BumpAugust 5, 2026 | seekingalpha.comSavara (SVRA) Gets a Buy from Piper SandlerJuly 24, 2026 | theglobeandmail.comWhat Savara Investors Should Know About This 580,187-Option Exercise and FDA TimelineJune 27, 2026 | fool.comSavara Announces New Employment Inducement GrantJune 12, 2026 | businesswire.comSavara Announces Chief Financial and Administrative Officer TransitionJune 8, 2026 | businesswire.comAssessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term ReturnsJune 8, 2026 | finance.yahoo.comOppenheimer Sticks to Their Buy Rating for Savara (SVRA)June 5, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)May 30, 2026 | theglobeandmail.comSavara Announces Participation in the 2026 Jefferies Global Healthcare ConferenceMay 27, 2026 | businesswire.comSavara: The Rare Disease Funnel Is Becoming A Commercial AssetMay 27, 2026 | seekingalpha.comSavara Inc. (SVRA) Reports Q1 Financial ResultsMay 22, 2026 | insidermonkey.com5 Best Penny Stocks to Buy for Long TermMay 21, 2026 | insidermonkey.comSavara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026May 20, 2026 | businesswire.comSavara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar ...May 19, 2026 | uk.finance.yahoo.comSavara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)May 19, 2026 | businesswire.comSavara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)May 18, 2026 | businesswire.comGuggenheim Reaffirms Their Buy Rating on Savara (SVRA)May 15, 2026 | theglobeandmail.comSavara (SVRA) Receives a Buy from Piper SandlerMay 15, 2026 | theglobeandmail.comSavara Reports First Quarter Financial Results and Provides Business UpdateMay 12, 2026 | businesswire.comAssessing Savara (SVRA) Valuation After FDA Extends Priority Review For MolgramostimApril 26, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Savara (SVRA) and Rhythm Pharmaceuticals (RYTM)April 17, 2026 | theglobeandmail.comSavara Announces New Employment Inducement GrantApril 17, 2026 | businesswire.comSavara gets FDA review extension for lead assetApril 16, 2026 | seekingalpha.comSavara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application ...April 15, 2026 | uk.finance.yahoo.comSVRA stock slips post-market after FDA delays decision on pulmonary therapyApril 15, 2026 | msn.comSavara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)April 15, 2026 | businesswire.comSavara To Present New Data at the American Thoracic Society (ATS) 2026 International ConferenceApril 14, 2026 | businesswire.comSavara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune ...April 7, 2026 | finance.yahoo.comSavara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)April 7, 2026 | businesswire.comAnalysts Offer Insights on Healthcare Companies: Savara (SVRA) and Edwards Lifesciences (EW)April 2, 2026 | theglobeandmail.comGuggenheim Keeps Their Buy Rating on Savara (SVRA)April 2, 2026 | theglobeandmail.comSavara Inc.April 1, 2026 | marketwatch.comSavara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune ...March 30, 2026 | uk.finance.yahoo.comSavara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)March 30, 2026 | businesswire.com Savara Media Mentions By Week Savara Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SVRA News Sentiment▼0.000.47▲Average Healthcare News Sentiment Savara News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SVRA Articles This Week▼14▲SVRA Articles Average Week Savara Trends on MarketBeatThis week vs. last weekNew Followers1-50%Searches1-50%Page Views4,227-23% Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TNGX News RLAY News ABCL News TLX News VKTX News VCYT News PBLS News LEGN News XENE News CDNA News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Savara dated 10/21/2026. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
